세계의 천식용 스페이서 시장(2023-2030년)

Overview

Inhaler spacers, holding chambers, and asthma spacers are all medical devices used to treat respiratory disorders like asthma. They are made to enhance the way medication is inhaled into the lungs using metered-dose inhalers (MDIs). Asthma spacers are essential in ensuring that patients take their prescription medication in its entirety, lowering the risk of side effects, and enhancing the overall efficacy of treatment.

The market for asthma spacers has been significantly impacted by the rising prevalence of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. The need for efficient respiratory medicine delivery methods, particularly spacers, has increased as these illnesses become more widespread.

The advantages of employing asthma spacers are now better understood by patients and healthcare practitioners. Spacers increase the effectiveness of drug delivery to the lungs, minimizing the chance of adverse effects and guaranteeing that patients receive the entire quantity of their prescription medications.

Market Dynamics: Drivers

The Increasing Prevalence of Asthma

A chronic respiratory condition called asthma enlarges and inflames the lungs' airways. As per the Lancet, the asthma statistics worldwide for 2020 reported that the number of persons with asthma, a total of 339 million worldwide, is rising. Although asthma can afflict people of any age, children are more likely than adults to get the condition. Although the exact cause of asthma is unknown, it is thought to be a result of both hereditary and environmental factors. Wheezing, coughing, chest tightness, and shortness of breath are all typical signs of asthma.

The Global Asthma Report 2022, prepared by Global Asthma Network, shows that Asthma affects roughly 35 million people in India. According to the report, underdiagnosis and insufficient treatment are significant obstacles to the fight against asthma in India. Asthma also affects a significant portion of children in India. Interventions for controlling asthma must start with community education and the prioritization of required drugs and supplies at the primary healthcare level.

For the treatment of asthma, the Zerostat VT Spacer Transparent inhaler space is intended. This item is made of high-quality materials and will last you for a very long time. A drug delivery system called a Zerostat VT Spacer Transparent Inhaler Space is used to treat asthma patients. It is an inhaler that employs the aerosolization method of operation.

Lack of Awareness and Education

Lack of knowledge regarding the advantages of employing asthma spacers and insufficient patient education on their proper use can impede market expansion. The benefits of utilizing spacers with inhalers may not be fully understood by many patients and healthcare professionals. Cost can be a major obstacle to the use of asthma spacers. These devices might be costly for some patients, especially if they do not have insurance or if they have to replace them regularly. Nebulizers and dry powder inhalers (DPIs) may be preferred by some patients over MDIs with spacers. Demand for asthma spacers may vary depending on individual preferences and level of comfort using particular devices.

Segment Analysis

The global asthma spacers market is segmented based on type, distribution channel and region.

The aerochambers segment accounted for approximately 45.6% of the market share

Aerochambers are cutting-edge medical tools made to make it easier for people with asthma, COPD, or other respiratory disorders to breathe. Aerochambers are made up of a plastic tube that allows the drug spray to reach the patient, a mask that goes over the face or a mouthpiece on the front, and sometimes a plastic cover for the medication that is being administered that is attached to the back.

Depending on the age range, different models of aerochambers are available. Some manufacturers opt for a distinct model for each age range, such as one for children aged 1-6 and another for those above the age of 6, while others use a single aerochamber with a detachable aerochamber mask.

Biosynex Aerochambers come in infant, child, and adult sizes and are assured to be latex and bisphenol A-free. They are a crucial component of effective respiratory disease treatment. Biosynex aerochambers are designed for people of all ages who still find it difficult to take the medication with a metered dose inhaler.

Geographical Penetration

The Increasing Prevalence of Ashma and Advanced Healthcare Infrastructure

North America has been a dominant force in the global asthma spacers market. Where a person lives has a big impact on their asthma. People with asthma have a better chance of managing and treating their condition if they have access to inexpensive, quality healthcare, clean air, and stable economic conditions.

In April 2023, the American Lung Association estimates that 41.9 million Americans have ever had an asthma diagnosis. A persistent illness that affects the airways is asthma. Chest pain, coughing, and wheezing are some symptoms that can come and go. All ages are affected by asthma; however, it most often develops in children.

One sort of spacer that has a one-way valve at the mouthpiece is a valved holding chamber. More than just "space" between the mouth and the medication is provided by these devices. Additionally, it holds and traps medication, allowing patients to take a moment to exhale deeply. This makes it possible to inhale the complete pharmaceutical dose.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide. People with pre-existing respiratory illnesses, such as asthma, became more aware of their health as a result of the pandemic, which brought to light the significance of respiratory health. The demand for asthma spacers and other breathing devices may have increased as a result of the greater awareness.

Telemedicine and remote monitoring are two strategies that many healthcare providers have used to lower the danger of exposure to COVID-19. Through virtual consultations, patients with asthma and other respiratory disorders may have received advice on how to use and manage devices, thereby increasing the adoption of spacers.

By Product Type

• Aerochamber
• Optichamber
• Volumatic
• Inspirease

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• E-Commerce

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include: Cipla Inc, Koninklijke Philips N.V., Deposition Pulmonaire des Medicaments SAS, Monaghan Medical Corporation, Truedell Medical International, Duomed, PARI GmbH, Laboratoire ProtecSom and Haag-streit group among others.

Why Purchase the Report

• To visualize the global asthma spacers market segmentation based on type, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of asthma spacers market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global asthma spacers market report would provide approximately 46 tables, 53 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Distribution Channel
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Increasing Prevalence of Asthma
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of Awareness and Education
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. SWOT Analysis
• 5.7. Patent Analysis
• 5.8. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Aerochamber*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Optichamber
• 7.4. Volumatic
• 7.5. Inspirease

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Retail Pharmacy*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Hospital Pharmacy
• 8.4. E-Commerce

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. UK
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Cipla Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Koninklijke Philips N.V.
• 11.3. Deposition Pulmonaire des Medicaments SAS
• 11.4. Monaghan Medical Corporation
• 11.5. Duomed
• 11.6. Others

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us